Introduction
Acute promyelocytic leukaemia (APL) is characterised by the t (15;17) , which produces the PML-RAR␣ fusion gene. [1] [2] [3] Transcripts for PML-RAR␣ are detected in all patients with t (15;17) . The breakpoints on chromosome 17 were located in the second intron of the RARA gene in all cases with t(15;17), whereas there are three different breakpoint cluster regions (BCR1, BCR2, BCR3) on chromosome 15 . This leads to the formation of three types of PML-RAR␣ transcripts. BCR1 and BCR3 are most frequently involved in APL (92-95% of cases) and produce a unique PML-RAR␣ fusion gene, whereas BCR2 leads to several different products due to different breakpoints within this cluster. 4 The combination of all-trans retinoic acid (ATRA) and chemotherapy has made it possible for up to 90% of patients to achieve complete remission (CR). However, relapse still occurs in some 15-25% of patients, indicating the need for an accurate protocol for the monitoring of minimal residual disease (MRD) in these patients. Such a protocol may enable the identification of patients at high risk of relapse and predict its onset at an early stage. RT-PCR methods developed for the amplification of PML-RAR␣ transcripts have been used for diagnosis and in monitoring minimal residual disease (MRD). [5] [6] [7] [8] [9] [10] [11] [12] Serial negative tests for the PML-RAR␣ transcripts in post-chemotherapy patients are generally associated with prolonged remission. However, up to 25% of those patients can relapse within a short period of testing negative. [10] [11] [12] [13] This is due in part to the low level of sensitivity of these methods, approximately 10 −4 , which is 2 log lower than corresponding methods for other fusion genes such as AML1-MTG8.
14 These methods lack the necessary sensitivity to detect the presence of low levels of leukaemic cells present during stable remission.
It is clear from the data reported by various groups on MRD monitoring of APL that a sensitive quantitation of PML-RAR␣ may provide a superior strategy for MRD monitoring in these patients. Recently, protocols for real-time quantitation of PML-RAR␣ have been developed, but these small studies have produced mixed results. 15, 16 Evaluation of real-time quantitation of PML-RAR␣ by various groups is in progress.
We have developed a highly sensitive competitive RT-PCR method for the quantitation of PML-RAR␣ transcripts and have assessed its value in monitoring MRD in 16 patients with APL and t(15;17).
Materials and methods

Patients
Serial bone marrow (BM) and peripheral blood (PB) samples were collected from 16 patients in complete remission (CR) of APL with a CR duration of 9-94 months (median 32 months). Three of the patients were tested at presentation. Diagnosis of APL (AML M3) was made according to FAB classification 17 and the presence of t(15;17) was confirmed by karyotypic analysis. All patients received standard intensive remission induction chemotherapy with an anthracycline/ anthracenedione (daunorubicin or mitozantrone), cytosine arabinoside ± thioguanine and two courses of consolidation chemotherapy with the same agents, followed by autologous or allogeneic bone marrow transplant (BMT) in four patients. Patients who did not receive BMT received a fourth course of intensive chemotherapy with mitozantrone and an intermediate dose of cytosine arabinoside. Three patients received short courses of ATRA 5-7 days prior to induction chemotherapy. Five patients received concomitant ATRA with induction chemotherapy until achievement of remission. Pre-BMT conditioning was comprised of daunorubicin (60 mg/m 2 ), cyclophosphamide (120 mg/m 2 ) and TBI (1000 cGy) in two fractions for allograft or melphalan (120 mg/m 2 ) and TBI for autograft. The remission BM karyotypes were normal in all patients.
Samples and RNA preparation
Mononuclear cells (MNCs) from PB and BM samples were obtained by Ficoll-Hypaque density gradient centrifugation and either stored at −80°C or used immediately for RNA isolation. Between 1 × 10 6 and 2 × 10 6 cells from the NB4 cell line or patients' MNCs were used for RNA isolation by the guanidinium-phenol-chloroform method of Chomczynski and Sacchi 18 with minor modifications as described previously.
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RT reaction
Four l (1-5 g) of RNA was heated at 72°C for 5 min and snap cooled on ice. RT reaction mixture (final concentration in a 20 l reaction volume: 1× first strand buffer, 10 mM DTT, 0.25 g pd(N)6, 1 mM dNTPs, 200 U MMLV, 40 U RNAsin) was then added to the RNA and incubated at room temperature for 10 min. RT reaction was carried out at 37°C for 1 h, 45°C for 30 min and 72°C for 5 min.
Control gene (ABL RT-PCR)
To assess the quality and estimate the quantity of amplifiable RNA used for RT-PCR, qualitative and quantitative RT-PCR amplification of ABL gene transcripts was performed. PCR amplification was performed as previously described; 20 briefly, PCR amplification was performed in a 25 l reaction containing primers CA3 and A2 at 97°C for 1 min 30 s, 64°C for 50 s and 72°C for 1 min, (one cycle); 97°C for 30 s, 64°C for 50 s and 72°C for 1 min (40 cycles) and 72°C for 5 min (one cycle). PCR products were electrophoresed on a 2% agarose gel.
PML-RAR␣ RT-PCR
Three l of cDNA were subjected to two rounds of transcriptspecific PCR amplification for the PML-RAR␣ transcripts. The first round PCR was performed in a 50 l reaction containing 1 U of Amplitaq gold DNA polymerase (Perkin Elmer, Warrington, UK) and primers NP2 and 8 for BCR1 transcript, or primers NP51 and 8 for BCR3 transcript (Table 1) . PCR ampli- Table 1 Sequence of primers used in this study Primer Sequence 5Ј-3Ј   A2  TTCAGCGGCCAGTAGCATCTGACTT  CA3  TGTTGACTGGCGTGATGTAGTTGCTTGG  NP2  AGTGGCGCCGGGGAGGCAGCCA  NP32  GGCGCCGGGGAGGCAGCCA  NP51  TCTTGCATCACCCAGGGGAAAGCC  NP5  TGCATCACCCAGGGGAAAGCC  CPMR3 GCCAGTGGCGCCGGGGAGGCAGCCACCAGCTTCC  AGTTAGTGGA  CPMR5 AGCTCTTGCATCACCCAGGGGAAAGCCACCAGCTT  CCAGTTAGTGGA  7  TCTTCTGGATGCTGCGGCGG  8  GGCGCTGACCCCATAGTGGT  RAR  AGGGCTGGGCACTATCTCTTC  M4  AGCTGCTGGAGGCCTGTGGACGCGCGGTACC  2  TGTGCTGCAGCGCATCCGCA  R8 CAGAACTGCTGCTCTGGGTCTCAAT Leukemia fication parameters were 95°C for 12 min (one cycle); 93°C for 1 min, 56°C for 1 min and 72°C for 1 min (50 cycles); and 72°C for 5 min (one cycle). Two l of first round product were used in a 50 l second round PCR reaction containing primers NP32 and RAR for BCR1 and NP5 and RAR for BCR3. PCR parameters were 95°C for 12 min (one cycle); 93°C for 1 min, 56°C for 1 min and 72°C for 1 min (40 cycles); and 72°C for 5 min (one cycle). Second round products were electrophoresed on a 2.5% agarose gel.
ABL competitive RT-PCR
A competitive RT-PCR method was used to quantitate the ABL transcript. 19 This quantitation was used to accurately estimate the level of amplifiable RNA present in samples. Two l of cDNA were mixed with 2 l of ABL transcript competitor DNA and subjected to a one round PCR amplification as described above. The expected band sizes for ABL and competitor are 276 bp and 235 bp, respectively.
RAR␣ competitive RT-PCR
Competitors for BCR1 and BCR3 types of PML-RAR␣ transcripts were prepared by PCR amplification of the normal RAR␣ transcripts with primers cpmr5 and 7 or cpmr3 and 7. The sense primers, cpmr5 and cpmr3, have tails containing sequences of primers NP3 and NP32 or NP51 and NP5 that are used in PCR amplification respectively (Figure 1) . None of our patients have a BCR2 fusion transcript, but a similar approach could be used to prepare BCR2 competitors. Three l of PML-RAR␣ positive samples' cDNA were mixed with 2 l of competitor DNA and subjected to PCR amplification as described above. Each sample was quantified at every order of magnitude and then at every half order of magnitude. Reactions that produce equal intensity bands for the transcripts and competitor were estimated to contain 1.7× the number of competitor molecules in the reaction (the size of competitor/transcript). The level of PML-RAR␣ present in Figure 1 Schematic diagram of the synthesis of competitors for the BCR1 and BCR3 PML-RAR␣ transcripts.
samples was normalised to the number of copies of PML-RAR␣ transcripts/10 5 copies of ABL transcript.
ABL and PML-RAR␣ degradation rates
Samples from two patients and the NB4 cell line were divided into three parts: one part was Ficolled as described above then frozen directly at −80°C; the other two parts were incubated at room temperature for 24 and 48 h, respectively, before being Ficolled. The levels of ABL and PML-RAR␣ transcripts were estimated in all three portions to estimate the rate of degradation. In one experiment all three parts were frozen at −80°C before proceeding with the estimation of the levels of ABL and PML-RAR␣ transcripts.
Reproducibility and accuracy of assays
In all tests, negative and positive controls were used. Negative controls included reaction with no RNA, no cDNA or t(15;17)-negative cell lines, such as K562. The NB4 cell line was used as a positive control. All necessary precautions were taken to avoid contamination. These included the use of especially designed UV-flow cabinet, PCR-designated pipettes and filtered tips for all PCR preparations. Tests were repeated twice to confirm the results.
Sensitivity analysis
Normal MNCs were used to make serial dilutions from the NB4 cell line, 21 which has a BCR1 PML-RAR␣ fusion gene, or a presentation sample from an APL patient with a BCR3 PML-RAR␣. These dilutions were used in comparing sensitivity of different methods for the amplification of PML-RAR␣. 22 Three l of cDNA were added to a final volume of 50 l of first round PCR reaction buffer containing as final concentrations: 1× PCR buffer (Gibco-BRL, Paisley, UK), 0.2% W-1 (detergent; Gibco-BRL), 1.5 mM MgCl 2 , 0.25 mM dNTPs, 15 pmol of primers M4 and RAR (Table 1) , 2 U Taq DNA polymerase. Amplification was performed for one cycle at 94°C for 2 min, followed by 40 cycles at 93°C for 1 min, 55°C for 1 min, 72°C for 1 min, and finally one cycle at 72°C for 5 min. Five l of first round PCR product was added to a final volume of 50 l of second round reaction buffer containing 15 pmol of primers 2 and R8 (Table 1) . PCR amplification was carried out as for the first round.
Standard qualitative RT-PCR amplification of PML-RAR␣ transcripts
Second-round PCR products were electrophoresed on a 2% agarose gel.
Results
Sensitivity analysis
Sensitivity of the transcript-specific amplification of both BCR1 and BCR3 PML-RAR␣ was 10 −5 after one round of PCR
Figure 2
Sensitivity assay of the transcript-specific amplification of PML-RAR␣. N, negative control; M, molecular weight marker. and 10 −6 after two rounds of PCR (Figure 2 ). This method can detect as few as three copies of the PML-RAR␣ transcript.
Linearity and reproducibility of results
Serial dilutions of NB4 cell line were prepared with normal MNCs and subjected to competitive RT-PCR analysis to assess the accuracy and reproducibility of results achieved with this method. Our data show this method to be accurate and linear over a wide range of PML-RAR␣ transcript levels. The points of equivalence for 10 Figure 3 shows an example of this analysis. All experiments were repeated to confirm the levels of transcripts in each sample.
Figure 3
Linearity studies of competitive PCR. 
ABL and PML-RAR␣ degradation rates
The degradation rates of ABL and PML-RAR␣ transcripts were equal. Both transcripts decreased by 0.5 log after 24 h and 1 log after 48 h. RNA and cDNA samples stored at -80°C for up to 2 months showed no significant degradation of either transcript.
PML-RAR␣ quantitation
The level of PML-RAR␣ transcripts was quantified in sequential BM and PB samples from 16 patients with APL. Two of the 16 patients who achieved remission subsequently relapsed. We have examined three patients at presentation of their disease (three BM, one PB). The levels of PML-RAR␣ transcripts at presentation were found to be in the range of 0.7 × 10 6 -3.5 × 10 6 molecules in BM samples and 1.2 × 10 5 molecules in PB samples (Figures 4 and 5) . Quantitation of MRD by RT-PCR analysis in 16 patients showed a significant reduction in the level of PML-RAR␣ transcripts after the induction of CR as compared to levels at presentation in both BM (11 patients) and PB (eight patients).
While the level of PML-RAR␣ transcripts became undetectable in two patients during durable remission, the majority of patients continue to express detectable levels of fusion transcripts even in long-term remission (9-94 months, median 32 months). There were no significant differences in the level of ABL transcripts/reaction between negative and positive samples. There was no difference in the levels of PML-RAR␣ during CR between patients who received different treatment (chemotherapy or BMT). In all patients in stable remission the level of PML-RAR␣ was found to be up to 2 × 10 2 molecules in BM samples and up to 5.2 × 10 1 molecules in PB samples (Figures 4 and 5) . BM examination for patients in remission showed that samples were both morphologically and karyotypically normal.
Examination of the level of PML-RAR␣ transcript in one BM
Leukemia
Figure 5
Levels of PML-RAR␣ and PB samples from different phases of APL in BM and PB samples from 16 patients. P, presentation (, ); CR, remission (b, ᭺); CR/BR, remission/before relapse (̆, ̅); R, relapse (᭜, ᭛).
sample in second remission showed a significantly higher level of fusion transcript (1.2 × 10 4 ) than those detected during stable remission. This patient relapsed 4 months later ( Figure  4 , patient 2). Three PB samples taken between 2 and 3 months before relapse also showed significantly higher levels of PML-RAR␣ transcripts (3.5 × 10 2 , 1.2 × 10 2 and 1.2 × 10 3 ) than those detected in samples from patients in stable remission (Figure 4, patients 1 and 2) . When we examined the same samples, using the same cDNAs, with a standard qualitative RT-PCR protocol, with a sensitivity of 10 −4 (see Materials and methods), they were found to be negative for PML-RAR␣ ( Figure 6 ).
The level of PML-RAR␣ transcripts increased further at relapse. Two relapsed BM samples showed levels of 1 × 10 6 and 1 × 10 7 molecules of PML-RAR␣, while two relapsed PB samples showed levels of 1.2 × 10 5 and 3.5 × 10 5 molecules of PML-RAR␣ (Figures 4 and 5) .
Discussion
APL is highly responsive to ATRA and to chemotherapy, and has a favourable clinical outcome. However, relapse remains a major problem. Predicting early relapse in patients may provide the opportunity to offer these patients additional or alternative treatment such as ATRA, Aasenic trioxide or BMT. Monitoring MRD in APL has not been efficient in identifying all patients at high risk of relapse. To date, monitoring MRD in APL has been based on the detection of PML-RAR␣ transcripts with qualitative RT-PCR methods that have a low sensitivity level of 10 . This may explain the failure of these methods to detect early significant changes in the level of PML-RAR␣ transcripts before the onset of haematological relapse. This failure was most noticeable in patients who relapse within short periods of negative PML-RAR␣ tests with these protocols. Up to 25% of patients tested negative with these protocols relapsed shortly afterwards. [10] [11] [12] [13] Large studies that used qualitative RT-PCR protocols for MRD monitoring have produced variable data. Diverio et al 23 showed that the relapse rate was 95% in patients who are PCR positive during remission and 5% in PCR-negative patients. Burnett et al, 24 on the other hand, showed that the relapse rate was 57% in PCR-positive patients and 27% in PCR-negative patients. These findings indicate that a sensitive RT-PCR method coupled with a quantitative approach for PML-RAR␣ transcripts is required for efficient monitoring of MRD in APL. Such quantitative protocols may provide a superior approach for identifying patients at high risk of relapse, at an early stage, who then may be offered additional or alternative treatment to prevent the onset of haematological relapse. Indeed preliminary data, reported by Lo Coco et al, 25 indicate that pre-emptive administration of salvage therapy at the time of molecular relapse is beneficial in APL.
Recently, we have shown that using a sensitive competitive RT-PCR strategy for the quantitation of MRD in t(8;21) AML can identify patients in durable remission and predict clinical relapse. 19 Protocols have been developed in recent years to quantitate PML-RAR␣ transcripts using real-time quantitation strategies. 15, 16 The value of these methods in MRD monitoring has not been fully assessed yet. We have described here a highly sensitive competitive RT-PCR method for the amplification and quantitation of PML-RAR␣ transcripts.
The use of transcript-specific RT-PCR for the various types of PML-RAR␣ transcripts enabled us to avoid the amplification of unnecessary PML sequences. We have shown in previous work that the inclusion of these PML sequences reduces the sensitivity of PML-RAR␣ detection. 22 Using this strategy, we were able to achieve a sensitivity of 10 −5 with one round of PCR and 10 −6 with two rounds of PCR. This sensitivity is comparable to that achieved for other fusion transcripts such as AML1-MTG8.
14 Tests performed on serial dilutions of NB4 cell line showed this method to have equal efficiency of amplification for the PML-RAR␣ transcripts and the competitors. These tests also showed the quantitation to be linear over a wide range of fusion transcripts level.
Our data showed the persistence of leukaemic cells expressing the PML-RAR␣ transcripts in long-term remission patients and indicate that disease-free remission is not inconsistent with the presence of a small number of leukaemic cells. These data are in accordance with the findings we reported earlier. 22 Quantitation of PML-RAR␣ transcripts showed a significant decrease in the number of PML-RAR␣ transcripts after chemotherapy, which imply a reduction in the number of leukaemic cells, when patients respond to treatment.
Levels of fusion transcripts in presentation samples were in the range of 0.7 × 10 6 -3.5 × 10 6 molecules in BM samples and 1.2 × 10 5 molecules in PB samples. In stable remission the levels of PML-RAR␣ were significantly lower, but remain detectable in the majority of samples, even though BM examination for patients in remission showed that samples were both morphologically and karyotypically normal. Up to 2 × 10 2 molecules were detected in BM samples and up to 5.2 × 10 1 molecules were detected in PB samples during stable remission. Our data show that PML-RAR␣ levels increased significantly up to 4 months before the onset of clinical relapse in two patients. Our examination of one BM sample, 4 months before relapse, showed 1.2 × 10 4 molecules of PML-RAR␣. Three PB samples taken between 2 and 3 months before relapse also showed significantly higher levels of PML-RAR␣ transcripts (3.5 × 10 2 , 1.2 × 10 2 and 1.2 × 10 3 molecules). Examining the same samples with a standard qualitative RT-PCR protocol (see Materials and methods section) showed these samples to be negative for PML-RAR␣. This examination indicates that the qualitative protocol could not have predicted the clinical relapse experienced by these patients.
In summary, our results on this small series of patients with APL and t(15;17) have shown that a sensitive and accurate quantitation of PML-RAR␣ fusion transcripts may provide a superior approach for monitoring MRD in these patients than the qualitative RT-PCR approach used to date. We suggest that PB samples may provide an alternative source for monitoring MRD in APL patients, which may help in avoiding the inconvenience of BM sampling. The efficiency of PML-RAR␣ quantitation in identifying patients at high risk of relapse requires further evaluation in larger series of patients.
